{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T05:19:10Z","timestamp":1680844750541},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Androgen deprivation therapy (ADT) is the effective treating prostate cancer but is often accompanied by cancer treatment-induced bone loss (CTIBL), which impairs the patient\u2019s quality of life. In patients with nonmetastatic castration-sensitive prostate cancer (M0CSPC) who already have osteoporosis before starting ADT, appropriate bone-modifying agent intervention must be performed in parallel, as the patient has a high risk of future fracture. However, little is known about therapeutic interventions aimed at preventing the progression of CTIBL and new fractures. The present study explored the effect of once-yearly zoledronic acid 5\u2009mg (ZOL 5\u2009mg) on bone mineral density (BMD) and new vertebral fractures (VFs) in M0CSPC patients with coexisting osteoporosis before starting ADT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective, multi-institutional, cohort study involving 42 M0CSPC patients with osteoporosis who had undergone ADT with\/without a single intravenous infusion of ZOL 5\u2009mg at the start of ADT (ZOL 5\u2009mg group, <jats:italic>n<\/jats:italic>\u2009=\u200926; control group, <jats:italic>n<\/jats:italic>\u2009=\u200916). The association of the ZOL 5\u2009mg with changes in the BMD from baseline to 12\u2009months and the incidence of VFs were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Prevalent VFs were found in 47.6% of all patients at baseline. ZOL 5\u2009mg significantly increased the lumbar spine BMD (LS-BMD) (mean rate of change: +\u20094.02%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and significantly decreased the TRACP-5b (mean rate of change: \u2212\u200952.1%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) at 12\u2009months after starting ADT. Incident VFs were identified in 19.0% of all patients at 12\u2009months after starting ADT. After adjusting for the age, BMI, and changes in the LS-BMD, ZOL 5\u2009mg was not significantly associated with incident VFs (odds ratio 0.66, 95% confidence interval 0.04\u201311.3, <jats:italic>p<\/jats:italic>\u2009=\u20090.7774).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ZOL 5\u2009mg significantly increased the LS-BMD 12\u2009months after starting ADT, and our short-term results showed that ZOL 5\u2009mg was not significantly correlated with the suppression of incident vertebral fractures.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08177-w","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:02:46Z","timestamp":1618617766000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis"],"prefix":"10.1186","volume":"21","author":[{"given":"Daisuke","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadaaki","family":"Minowa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akemi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichiro","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Mizushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,17]]},"reference":[{"issue":"3","key":"8177_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jama.2011.2022","volume":"307","author":"SM Alibhai","year":"2012","unstructured":"Alibhai SM, Yun L, Cheung AM, Paszat L. Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA. 2012;307(3):255\u20136. https:\/\/doi.org\/10.1001\/jama.2011.2022.","journal-title":"JAMA"},{"issue":"10","key":"8177_CR2","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/jbmr.4106","volume":"35","author":"AS Cheung","year":"2020","unstructured":"Cheung AS, Hoermann R, Ghasem-Zadeh A, Tinson AJ, Ly V, Milevski SV, et al. Differing effects of Zoledronic acid on bone microarchitecture and bone mineral density in men receiving androgen deprivation therapy: a randomized controlled trial. J Bone Miner Res. 2020;35(10):1871\u201380. https:\/\/doi.org\/10.1002\/jbmr.4106.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"8177_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00774-020-01087-0","volume":"38","author":"S Fukumoto","year":"2020","unstructured":"Fukumoto S, Soen S, Taguchi T, Ishikawa T, Matsushima H, Terauchi M, et al. Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR. J Bone Miner Metab. 2020;38(2):141\u20134. https:\/\/doi.org\/10.1007\/s00774-020-01087-0.","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"8177_CR4","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1464-410X.2012.11758.x","volume":"111","author":"YH Shao","year":"2013","unstructured":"Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int. 2013;111(5):745\u201352. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11758.x.","journal-title":"BJU Int"},{"issue":"9992","key":"8177_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9992):433\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(15)60995-3.","journal-title":"Lancet"},{"issue":"3","key":"8177_CR6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","volume":"168","author":"MG Oefelein","year":"2002","unstructured":"Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168(3):1005\u20137. https:\/\/doi.org\/10.1016\/S0022-5347(05)64561-2.","journal-title":"J Urol"},{"issue":"1","key":"8177_CR7","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1186\/s12885-015-1843-3","volume":"15","author":"A Wang","year":"2015","unstructured":"Wang A, Obertova Z, Brown C, Karunasinghe N, Bishop K, Ferguson L, et al. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand. BMC Cancer. 2015;15(1):837. https:\/\/doi.org\/10.1186\/s12885-015-1843-3.","journal-title":"BMC Cancer"},{"issue":"8","key":"8177_CR8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745\u201355. https:\/\/doi.org\/10.1056\/NEJMoa0809003.","journal-title":"N Engl J Med"},{"key":"8177_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","volume":"7","author":"H Orimo","year":"2012","unstructured":"Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, et al. Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary. Arch Osteoporos. 2012;7:3\u201320.","journal-title":"Arch Osteoporos"},{"issue":"7","key":"8177_CR10","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/jbmr.5650110716","volume":"11","author":"HK Genant","year":"1996","unstructured":"Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis the study of osteoporotic fractures research group. J Bone Miner Res. 1996;11(7):984\u201396. https:\/\/doi.org\/10.1002\/jbmr.5650110716.","journal-title":"J Bone Miner Res"},{"issue":"11","key":"8177_CR11","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/ki.2008.356","volume":"74","author":"MA Perazella","year":"2008","unstructured":"Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008;74(11):1385\u201393. https:\/\/doi.org\/10.1038\/ki.2008.356.","journal-title":"Kidney Int"},{"issue":"9\u201310","key":"8177_CR12","first-page":"499","volume":"52","author":"JM Halleen","year":"2006","unstructured":"Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Vaananen HK. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab. 2006;52(9\u201310):499\u2013509.","journal-title":"Clin Lab"},{"issue":"10","key":"8177_CR13","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/jbmr.119","volume":"25","author":"ES Orwoll","year":"2010","unstructured":"Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010;25(10):2239\u201350. https:\/\/doi.org\/10.1002\/jbmr.119.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"8177_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/cncr.20766","volume":"103","author":"T Tanvetyanon","year":"2005","unstructured":"Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer. 2005;103(2):237\u201341. https:\/\/doi.org\/10.1002\/cncr.20766.","journal-title":"Cancer"},{"issue":"2","key":"8177_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375\u201382. https:\/\/doi.org\/10.1016\/j.bone.2004.03.024.","journal-title":"Bone"},{"issue":"4","key":"8177_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","volume":"15","author":"CM Klotzbuecher","year":"2000","unstructured":"Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15(4):721\u201339. https:\/\/doi.org\/10.1359\/jbmr.2000.15.4.721.","journal-title":"J Bone Miner Res"},{"issue":"10","key":"8177_CR17","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/iju.14077","volume":"26","author":"T Kimura","year":"2019","unstructured":"Kimura T, Koike Y, Aikawa K, Kimura S, Mori K, Sasaki H, et al. Short-term impact of androgen deprivation therapy on bone strength in castration-sensitive prostate cancer. Int J Urol. 2019;26(10):980\u20134. https:\/\/doi.org\/10.1111\/iju.14077.","journal-title":"Int J Urol"},{"issue":"1","key":"8177_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00774-017-0897-5","volume":"37","author":"S Kato","year":"2019","unstructured":"Kato S, Kawase M, Kato D, Ishida T, Uno M, Fujimoto Y, et al. Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy. J Bone Miner Metab. 2019;37(1):72\u201380. https:\/\/doi.org\/10.1007\/s00774-017-0897-5.","journal-title":"J Bone Miner Metab"},{"key":"8177_CR19","doi-asserted-by":"publisher","unstructured":"Watanabe D, Takano H, Kimura T, Yamashita A, Minowa T, Mizushima A. The relationship of diffuse idiopathic skeletal hyperostosis, visceral fat accumulation, and other age-related diseases with the prevalent vertebral fractures in elderly men with castration-naive prostate cancer. Aging Male. 2020:1\u20136. https:\/\/doi.org\/10.1080\/13685538.2020.1815694.","DOI":"10.1080\/13685538.2020.1815694"},{"issue":"6","key":"8177_CR20","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","volume":"169","author":"MR Smith","year":"2003","unstructured":"Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169(6):2008\u201312. https:\/\/doi.org\/10.1097\/01.ju.0000063820.94994.95.","journal-title":"J Urol"},{"issue":"4","key":"8177_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3816\/CGC.2007.n.003","volume":"5","author":"RS Israeli","year":"2007","unstructured":"Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer. 2007;5(4):271\u20137. https:\/\/doi.org\/10.3816\/CGC.2007.n.003.","journal-title":"Clin Genitourin Cancer"},{"key":"8177_CR22","doi-asserted-by":"publisher","first-page":"176164","DOI":"10.1155\/2011\/176164","volume":"2011","author":"A Kapoor","year":"2011","unstructured":"Kapoor A, Gupta A, Desai N, Ahn H. Effect of zoledronic acid on bone mineral density in men with prostate cancer receiving gonadotropin-releasing hormone analog. Prostate Cancer. 2011;2011:176164.","journal-title":"Prostate Cancer"},{"issue":"5","key":"8177_CR23","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/j.juro.2009.07.046","volume":"182","author":"N Bhoopalam","year":"2009","unstructured":"Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, et al. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol. 2009;182(5):2257\u201364. https:\/\/doi.org\/10.1016\/j.juro.2009.07.046.","journal-title":"J Urol"},{"issue":"3","key":"8177_CR24","first-page":"5170","volume":"17","author":"R Casey","year":"2010","unstructured":"Casey R, Gesztesi Z, Rochford J. Long term zoledronic acid during androgen blockade for prostate cancer. Can J Urol. 2010;17(3):5170\u20137.","journal-title":"Can J Urol"},{"issue":"3","key":"8177_CR25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/bju.12497","volume":"114","author":"JW Denham","year":"2014","unstructured":"Denham JW, Nowitz M, Joseph D, Duchesne G, Spry NA, Lamb DS, et al. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the trans-Tasman radiation oncology group (TROG) 03.04 randomised androgen deprivation and radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer. BJU Int. 2014;114(3):344\u201353. https:\/\/doi.org\/10.1111\/bju.12497.","journal-title":"BJU Int"},{"issue":"9","key":"8177_CR26","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","volume":"25","author":"MD Michaelson","year":"2007","unstructured":"Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25(9):1038\u201342. https:\/\/doi.org\/10.1200\/JCO.2006.07.3361.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8177_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154\u201364. https:\/\/doi.org\/10.1056\/NEJMoa041943.","journal-title":"N Engl J Med"},{"issue":"12","key":"8177_CR28","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s001980170006","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001;12(12):989\u201395. https:\/\/doi.org\/10.1007\/s001980170006.","journal-title":"Osteoporos Int"},{"issue":"20","key":"8177_CR29","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/archinte.165.20.2414","volume":"165","author":"DH Solomon","year":"2005","unstructured":"Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165(20):2414\u20139. https:\/\/doi.org\/10.1001\/archinte.165.20.2414.","journal-title":"Arch Intern Med"},{"key":"8177_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11657-015-0231-6","volume":"10","author":"H Kishimoto","year":"2015","unstructured":"Kishimoto H, Maehara M. Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Arch Osteoporos. 2015;10:231.","journal-title":"Arch Osteoporos"},{"key":"8177_CR31","doi-asserted-by":"publisher","unstructured":"Kimura T. Multidisciplinary approach for bone metastasis: a review. Cancers. 2018;10(6):156. https:\/\/doi.org\/10.3390\/cancers10060156.","DOI":"10.3390\/cancers10060156"},{"issue":"3","key":"8177_CR32","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.urology.2005.03.070","volume":"66","author":"K McGreevy","year":"2005","unstructured":"McGreevy K, Hoel B, Lipsitz S, Bissada N, Hoel D. Racial and anthropometric differences in plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein-3. Urology. 2005;66(3):587\u201392. https:\/\/doi.org\/10.1016\/j.urology.2005.03.070.","journal-title":"Urology"},{"issue":"1","key":"8177_CR33","first-page":"13","volume":"2","author":"ME van Houten","year":"2000","unstructured":"van Houten ME, Gooren LJ. Differences in reproductive endocrinology between Asian men and Caucasian men--a literature review. Asian J Androl. 2000;2(1):13\u201320.","journal-title":"Asian J Androl"},{"issue":"6","key":"8177_CR34","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1177\/1557988318793259","volume":"12","author":"P Mui","year":"2018","unstructured":"Mui P, Hill SE, Thorpe RJ Jr. Overweight and obesity differences across ethnically diverse subgroups of Asian American men. Am J Mens Health. 2018;12(6):1958\u201365. https:\/\/doi.org\/10.1177\/1557988318793259.","journal-title":"Am J Mens Health"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08177-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08177-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08177-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:02:50Z","timestamp":1618617770000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08177-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,17]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8177"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08177-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,17]]},"assertion":[{"value":"14 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study\u2019s retrospective protocol was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Koto Hospital (No. 202062, approved on Jun. 15, 2020) and The Jikei University School of Medicine (32\u2013123(10199), approved on Sep. 29, 2020). Patient consent was not required based on the use of anonymized data in this retrospective protocol, and the informed consent was waived by the Ethics Committee of Koto Hospital and The Jikei University School of Medicine that approved this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Takahiro Kimura is a paid consultant\/advisor of Astellas, Bayer, Janssen and Sanofi. The other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"422"}}